Further significant effects of eldecalcitol on bone resorption markers and bone mineral density in postmenopausal osteoporosis patients having undergone long-term bisphosphonate treatment

Abstract

We investigated whether eldecalcitol has further significant effects on bone metabolic markers and bone mineral density (BMD) in osteoporosis patients having undergone long-term bisphosphonate treatment. Eldecalcitol treatment was initiated in 48 postmenopausal osteoporosis patients who had undergone bisphosphonate treatment with or without alfacalcidol treatment for more than 2 years (average period 6.3 years). Age, height, weight, total muscle volume, total fat volume, estimated glomerular filtration rate, and BMD at the lumbar spine, total hip, and distal third of the radius were measured as background data for each patient. Serum alkaline phosphatase, tartrate-resistant acid phosphatase 5b, calcium, and phosphate levels were measured at the baseline and 3 and 12 months after the initiation of eldecalcitol treatment, and BMD was measured at the baseline and 12 months after the initiation of eldecalcitol treatment. Tartrate-resistant acid phosphatase 5b level was significantly decreased at 3 and 12 months after the initiation of eldecalcitol treatment in comparison with the baseline level. There were no significant changes in alkaline phosphatase, calcium, or phosphate levels in comparison with the baseline levels. In addition, the lumbar spine BMD at 12 months after the initiation of treatment was significantly increased in comparison with the baseline level, although no significant changes in BMD at the total hip and distal third of the radius were observed. Eldecalcitol demonstrated significant effects in additionally decreasing the level of the bone resorption marker tartrate-resistant acid phosphatase 5b and increasing BMD at the lumbar spine, even in osteoporosis patients having undergone long-term bisphosphonate treatment.

The therapeutic effect to eldecalcitol + bisphosphonate is superior to bisphosphonate alone in the treatment of osteoporosis: a meta-analysis

“…ELD can reduce the re-absorption of blood calcium into the bone, improve the absorption of calcium in the intestine, and then increase the bone density in osteoporosis patients [13]. A previous study shows that ELD has a significant effect in additionally decreasing the level of the bone resorption, even in the osteoporosis patients who undergo the long-time therapy of BP [37]. Actually, ELD + BP has been proven to be effective for the treatment of osteoporotic patients in Japan [38].…”

Efficacy and Safety of Eldecalcitol for Osteoporosis: A Meta-Analysis of Randomized Controlled Trials

“…ED-71 could reduce the re-absorption of blood calcium in the intestine and improve the BMD for patients with osteoporosis ( 15 ). The use of ED-71 could decrease the bone resorption level for patients treated with bisphosphonate ( 35 ). Furthermore, superior effects of ED-71 plus bisphosphonate on the risk of fractures at various sites were not detected.…”

Analysis of the Results of Laboratory Studies of Oral Fluid and Blood Serum of Patients in the Retention Period of Orthodontic Treatment

“…Остеокласты образуют продукты деградации, которые также выделяются в циркулирующую кровь и выводятся с мочой. Маркерами резорбции кости являются окси-и дезоксипиридинолины (PYR, DPYR), оксипролин (OHPr) и кальций в моче, N-и С-телопептиды молекул коллагена I типа, связанные поперечными сшивками (NTX, CTX) в сыворотке крови или моче, а также тартрат-резистентная кислая фосфатаза (TRACP) (КФ) [12] в плазме крови, характеризующая активность остеокластов. Маркеры образования и резорбции костной ткани в настоящее время используются для оценки скорости обмена кости и спаренности процессов ремоделирования [11].…”